Bio-Rad acquires AbD Serotec
Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.
AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.
“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.
“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”
Billion-dollar deal for UQ's molecular clamp vaccine tech
Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...
Director of scandal-ridden Forensic Science Queensland resigns
Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...
$492m pathology hub coming to Westmead Health Precinct
The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...
